Cambridge-based biotech company Alchemab has announced a new collaboration with British pharma AstraZeneca (AZ), aiming to accelerate research for prostate cancer.
Cambridge, UK-based Alchemab Therapeutics has raised £60m ($82m) in a Series A funding round, in a bid to advance its target-agnostic drug discovery platform.